Ensysce Biosciences, Inc. (ENSC) stock
Close on Nov 12, 2026Market cap $7.53MP/E –Yield –
Ensysce Biosciences, Inc. grew revenue 37.9% to $6.19M over the twelve months to Sep 30, 2026. Free cash flow was -$7.93M. At the latest close the market valued the company at $7.53M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $7.53M
- P/E ratio
- –
- Price to sales
- 1.22
- Price to book
- 0.27
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $6.19M
- EPS, diluted
- -$5.98
- Free cash flow
- -$7.93M
- Book value per share
- $1.51
- Diluted shares
- 18M
Trading
- Next earnings
- Nov 13, 2026 (estimated, after the close)
- Previous close
- $0.36
- Open
- $0.40
- Day's range
- $0.38 – $0.43
- Volume
- 391,354
- Average volume (20 days)
- 299,966
- Beta (5 years)
- 2.56
- 52-week range
- $0.23 – $2.17
- RSI (14 days)
- 43.5
- Volatility (1 year)
- 136.1%
- Relative volume
- 0.04×
- WACC
- 17.4%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ENSC | S&P 500 | Difference | ENSC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -30.3% | -2.7% | −27.7 pts | ||
| 3 months | -2.9% | -1.7% | −1.1 pts | ||
| Year to date | -57.9% | +11.9% | −69.8 pts | ||
| 1 year | -81.2% | +12.0% | −93.2 pts | ||
| 3 years | -96.8% | +78.2% | −175.0 pts | -68.2% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -86.3% | +11.6% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Ensysce Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- News
- Results
About Ensysce Biosciences
Pharmaceutical Preparations
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing proprietary drug platforms intended to prevent prescription drug abuse and overdose. Its technology includes Trypsin-Activated Abuse Protection (TAAP) and Multi-Programmed Abuse Resistance (MPAR), with lead opioid product candidates such as PF614 and PF614-MPAR designed for the management of severe to moderate chronic pain and the treatment of opioid use disorder. The company primarily targets patients requiring continuous analgesic therapy and healthcare markets affected by opioid misuse.
Company profile, executives and historyEnsysce Biosciences stock: common questions
What is Ensysce Biosciences's stock price?
ENSC closed at $0.39 on Nov 12, 2026, up 7.53% on the day. Over the past 52 weeks it traded between $0.23 and $2.17.
What is Ensysce Biosciences's market cap?
Ensysce Biosciences was worth $7.53M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ENSC's P/E ratio?
Ensysce Biosciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$5.98), so it has no meaningful P/E ratio.
How much revenue does Ensysce Biosciences make?
Ensysce Biosciences reported revenue of $6.19M for the twelve months to Sep 30, 2026, up 37.9% from a year earlier.
Does Ensysce Biosciences pay a dividend?
No. Ensysce Biosciences has not paid a cash dividend over the last twelve months.
When does Ensysce Biosciences report earnings next?
Ensysce Biosciences is expected to report Q3 FY2026 results on Nov 13, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ENSC stock performed over the past year?
Including dividends, ENSC returned -81.2% over the past year, against +12.0% for the S&P 500.
How many ENSC shares are sold short?
0M shares were sold short at the latest FINRA report, 0.49% of the float, or 1.0 days of average trading volume.
Who are Ensysce Biosciences's competitors?
Companies most similar to Ensysce Biosciences by business, industry and size include ANL, KYNB, RANI, BOLT, TRDA.
See a number that looks wrong?